SBC Medical Group Holdings (SBC) AI Stock Analysis

• Market Cap: $469.80M
• Dividend Yield: N/A
• Average Volume (3M): 65.67K
• Price to Earnings (P/E): 10.9
• Beta (1Y): 0.80
• Revenue Growth: 236.18%
• EPS Growth: N/A
• Country: US
• Employees: 863
• Sector: Industrials
• Sector Strength: 72
• Industry: Consulting Services
• EPS (TTM): 0.12
• Shares Outstanding: 102,576,940
• 10 Day Avg. Volume: 48,167
• 30 Day Avg. Volume: 65,672
• PEG Ratio: 0.74
• Price to Book (P/B): 2.75
• Price to Sales (P/S): 2.61
• P/FCF Ratio: 31.26
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 2.08
• Enterprise Value/Gross Profit: 2.82
• Enterprise Value/Ebitda: 5.10
• 1Y Price Target: $9.00
• Price Target Upside: 101.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: $5.00 ▲(11.86% Upside)

The score is driven by strong profitability and a low-leverage balance sheet, supported by constructive technical momentum. The main constraint is operational/cash-flow risk (negative operating cash flow and declining TTM revenue growth), while valuation appears reasonable (P/E ~10.3) and recent corporate actions are broadly positive.

Positive Factors

Strong Profitability

High profitability margins indicate efficient operations and pricing power, supporting long-term financial health and investment capacity.

Solid Balance Sheet

A low debt-to-equity ratio reflects prudent financial management, providing flexibility for future investments and resilience against economic downturns.

Strategic Acquisition

The acquisition of Waqoo strengthens SBC's R&D capabilities and market position in Japan, potentially driving innovation and revenue growth.

Negative Factors

Declining Revenue Growth

A decline in revenue growth may indicate challenges in market expansion or product demand, affecting long-term growth prospects.

Negative Operating Cash Flow

Negative operating cash flow suggests potential issues in cash generation from core operations, impacting liquidity and investment capacity.

Potential Dilution Risk

While providing funding flexibility, the shelf registration could lead to share dilution, impacting shareholder value if new equity is issued.

SBC Medical Group Holdings Business Overview & Revenue Model

Company Description

SBC Medical Group Holdings Incorporated provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and internationally. The company offers advertising and marketing services; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals and facility rentals; construction and design of franchisee clinics; medical equipment; and medical consumables procurement. It provides IT software solutions; breast augmentation, liposuction, and rejuvenation treatments, including treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging; laser skin toning and spot removal; eyes double fold surgery; rhinoplasty; treatment of osmidrosis and hyperhidrosis; hair transplants; gynecological formation treatments; laser hair removal; face line surgeries; cosmetical dental procedures; tattoo removal; lasik eye surgery; lateral canthoplasty; brow lift procedures; androgenetic alopecia treatment; and cheek sagging prevention methods. The company was founded in 2000 and is headquartered in Irvine, California.

How the Company Makes Money

SBC Medical Group Holdings generates revenue through multiple streams, primarily by selling its pharmaceutical products, medical devices, and healthcare technology solutions to hospitals, clinics, and healthcare providers. The company earns money from direct sales of its proprietary products as well as through licensing agreements and partnerships with other healthcare organizations. Additionally, SBC may engage in collaborations with research institutions for the development of new therapies, which can lead to revenue from shared intellectual property rights. The company's strong emphasis on research and development allows it to stay competitive in the market, attracting investment and funding for innovative projects, further contributing to its earnings.

SBC Medical Group Holdings Financial Statement Overview

Summary

Strong profitability (gross margin consistently above 70% and net margin up to 24.28% TTM) and a solid balance sheet (low debt-to-equity of 0.11; ROE 18.96%). Offsetting this, TTM revenue growth is down (-5.17%) and operating cash flow is negative despite strong free cash flow growth.

Income Statement

SBC Medical Group Holdings shows strong profitability with a consistent gross profit margin above 70% and a net profit margin improving to 24.28% in TTM. However, the revenue growth rate has declined by 5.17% in TTM, indicating potential challenges in maintaining top-line growth.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.11 in TTM, reflecting prudent financial management. Return on equity remains healthy at 18.96%, though slightly lower than previous years, indicating effective use of equity to generate profits.

Cash Flow

Cash flow metrics present a mixed picture. The free cash flow growth rate is positive at 210.12% in TTM, but operating cash flow is negative, raising concerns about cash generation from operations. The free cash flow to net income ratio is strong at 1.06, suggesting good cash conversion from profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	178.46M	205.42M	193.54M	174.16M
Gross Profit	131.52M	156.05M	137.30M	114.83M
EBITDA	72.59M	77.28M	85.87M	29.64M
Net Income	43.32M	46.61M	39.37M	6.32M
Balance Sheet
Total Assets	321.36M	266.08M	258.81M	225.48M
Cash, Cash Equivalents and Short-Term Investments	127.43M	125.04M	103.02M	53.64M
Total Debt	28.15M	12.21M	22.87M	16.13M
Total Liabilities	73.30M	71.06M	115.00M	117.63M
Stockholders Equity	247.99M	195.11M	142.16M	105.25M
Cash Flow
Free Cash Flow	-36.63M	17.17M	39.44M	-24.99M
Operating Cash Flow	-34.60M	20.58M	50.64M	-47.37K
Investing Cash Flow	-1.31M	-10.10M	1.82M	-32.65M
Financing Cash Flow	29.85M	22.97M	6.14M	-7.98M

SBC Medical Group Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.47
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBC, the sentiment is Positive. The current price of 4.47 is above the 20-day moving average (MA) of 4.40, above the 50-day MA of 4.09, and above the 200-day MA of 4.16, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 61.30 is Neutral, neither overbought nor oversold. The STOCH value of 47.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBC.

SBC Medical Group Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAI	78 Outperform	$1.24B	21.45	27.83%	0.97%	8.69%	34.58%
SBC	73 Outperform	$469.80M	10.89	19.13%	―	236.18%	―
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
FC	58 Neutral	$235.33M	-171.75	-2.08%	―	-7.02%	-86.27%
RGP	52 Neutral	$151.76M	-1.13	-61.44%	6.74%	-10.83%	-1669.11%
FORR	42 Neutral	$154.11M	-1.80	-43.39%	―	-8.73%	-1168.15%
AERT	41 Neutral	$25.15M	-23.80	―	―	-3.87%	-104.63%

SBC Medical Group Holdings Corporate Events

SBC Medical Enters U.S. Aesthetics Market With OrangeTwist

On January 5, 2026, SBC Medical Group Holdings completed a strategic minority equity investment in U.S.-based MedSpa chain OrangeTwist and entered into a structured collaboration framework with OrangeTwist and its institutional shareholders, Hildred Capital and Athyrium Capital, marking SBC Medical’s formal entry into the U.S. medical aesthetics market. The deal initiates Phase 1 of SBC Medical’s three-stage global expansion roadmap, centered on building a leading position in U.S. and international aesthetics and wellness through partnerships with high-performing regional operators, cross-border operational and clinical synergies between the U.S. and Asia, and a disciplined, multi-year plan to scale via acquisitions and joint ventures, underpinning its strategy to diversify revenues and strengthen its competitive positioning in high-growth health and wellness categories.

The most recent analyst rating on (SBC) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on SBC Medical Group Holdings stock, see the SBC Stock Forecast page.

SBC Medical Updates Capital Strategy and Repurchase Program

On December 31, 2025, SBC Medical Group Holdings announced an updated capital strategy aimed at supporting future growth and enhancing liquidity, following the U.S. Securities and Exchange Commission’s December 30, 2025 effectiveness of its Form S-3 shelf registration statement allowing up to $50 million of primary equity offerings. While not raising capital immediately, the shelf is intended to give the company flexibility to fund expansion, including domestic and international M&A and to increase its public float, while a newly approved share repurchase program of up to $20 million, running through December 31, 2026, signals management’s willingness to return capital to shareholders using surplus cash and free cash flow and could influence the trading dynamics and valuation of its common stock.

The most recent analyst rating on (SBC) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on SBC Medical Group Holdings stock, see the SBC Stock Forecast page.

SBC Medical Completes Acquisition of Waqoo Shares

On December 13, 2025, SBC Medical Group Holdings announced the final results of its tender offer for Waqoo, Inc., a Japanese medical R&D company specializing in regenerative medicine. The tender offer, conducted from November 14 to December 12, 2025, resulted in SBC Medical acquiring 575,052 shares at ¥1,900 per share. This acquisition, along with an off-market transaction with Waqoo’s largest shareholder, will increase SBC Medical’s ownership to over 50%, making it the parent company and largest shareholder of Waqoo. This strategic move enhances SBC’s healthcare technology capabilities and strengthens its presence in the Japanese market.

The most recent analyst rating on (SBC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on SBC Medical Group Holdings stock, see the SBC Stock Forecast page.

SBC Medical Group Announces Tender Offer for Waqoo

On November 13, 2025, SBC Medical Group Co., Ltd., a subsidiary of SBC Medical Group Holdings, announced the commencement of a tender offer to acquire shares of Waqoo, Inc., a Japanese corporation listed on the Tokyo Stock Exchange Growth Market. The tender offer, running from November 14 to December 12, 2025, aims to purchase up to 575,000 shares, with settlement expected on December 19, 2025. This strategic move is part of SBC’s plan to make Waqoo a consolidated subsidiary, enhancing its research and development initiatives and integrating Waqoo’s advanced technologies into SBC’s offerings. This acquisition is expected to strengthen SBC’s competitiveness in clinical areas such as AGA and orthopedics and support the development of new treatment methods and proprietary services.

The most recent analyst rating on (SBC) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on SBC Medical Group Holdings stock, see the SBC Stock Forecast page.